NEW YORK, NY / ACCESSWIRE / July 5, 2016 / Bronstein, Gewirtz & Grossman, LLC, notifies investors of class action against of Neovasc, Inc. ("Neovasc" or "the Company") (NVCN). The class action has been filed on behalf of a class consisting of all persons or entities who purchased Neovasc securities during the period between January 26, 2015, and May 19, 2016, inclusive (the "Class Period").
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act").
Neovasc is a specialty medical company that develops cardiovascular products. Neovasc's primary product is the Tiara, a transcatheter mitral valve device used to treat mitral valve disease. This device can be implanted through minimally invasive surgery to patients with mitral regurgitation resulting from mitral heart valve disease.
The Complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about Neovasc's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (1) Neovasc's Tiara device was advanced through dishonest business practices, including the embezzlement of trade secrets from another company; (2) that there was a related and legitimate lawsuit against Neovasc regarding the misappropriation of trades secrets; and (3) consequentially, Defendants' statements about Neovasc's business, operations, and prospects were materially false and misleading at relevant times. Following this information entering the market, investors suffered damages.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action, visit the firm's website: http://www.bgandg.com/#!nvcn/m3197. To discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Neovasc you have until August 5, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC